Get the Stockscreener App
2.18
6.03%
-0.14
After Hours:
2.28
0.10
+4.59%
Traws Pharma Inc stock is traded at $2.18, with a volume of 17,633.
It is down -6.03% in the last 24 hours and down -4.80% over the past month.
See More
Previous Close:
$2.32
Open:
$2.25
24h Volume:
17,633
Relative Volume:
0.15
Market Cap:
$10.97M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-15.18%
1M Performance:
-4.80%
6M Performance:
-60.72%
1Y Performance:
+0.00%
1-Day Range:
$2.10
$2.25
1-Week Range:
$2.01
$2.6918
52-Week Range:
$2.01
$19.44
Traws Pharma Inc Stock (TRAW) Company Profile
Name
Traws Pharma Inc
Sector
Industry
Phone
267-759-3680
Address
12 PENNS TRAIL, NEWTOWN
Compare TRAW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
2.18 | 10.97M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| May-18-21 | Initiated | Guggenheim | Buy |
| Mar-01-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-17-18 | Downgrade | Maxim Group | Buy → Hold |
| Oct-09-17 | Initiated | H.C. Wainwright | Buy |
| Apr-27-17 | Initiated | Laidlaw | Buy |
| Jul-01-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-05-15 | Initiated | H.C. Wainwright | Buy |
View All
Traws Pharma Inc Stock (TRAW) Latest News
Traws Pharma Reports 2024 Financial Results and Advances Bird Flu and COVID Programs - MSN
TRAW stock touches 52-week low at $2.01 amid sharp annual decline By Investing.com - Investing.com South Africa
TRAW stock touches 52-week low at $2.01 amid sharp annual decline - Investing.com India
Traws Pharma Reports 2024 Results and Strategic Progress - TipRanks
Traws Pharma Showcases Promising COVID-19 Drug at ICAR Conference - MSN
Earnings call transcript: Traws Pharma Q1 2025 shows innovation boost By Investing.com - Investing.com South Africa
Earnings call transcript: Traws Pharma Q1 2025 shows innovation boost - Investing.com
Traws Pharma Announces Virtual Investor Event to Showcase Innovative Treatments for Bird Flu and COVID-19 - MSN
Traws Pharma Reports 2024 Financial Results and CEO Change - TipRanks
Traws Pharma CEO Werner Cautreels to retire - MSN
Traws Pharma Reports Full Year 2024 Results and Business Highlights - GlobeNewswire
Traws Pharma's Bird Flu Drug Shows Promise Despite $166M Annual LossKey Updates - Stock Titan
Traws Pharma (TRAW) Expected to Announce Quarterly Earnings on Monday - Defense World
Traws Pharma Announces CEO Transition as Werner Cautreels Retires - MSN
Traws Pharma announces CEO retirement and interim successor By Investing.com - Investing.com South Africa
Traws Pharma announces CEO retirement and interim successor - Investing.com India
Traws Pharma CEO Werner Cautreels Retires, Chair Iain Duke Succeeds on Interim Basis - MarketScreener
Traws Pharma Announces Management Updates - GlobeNewswire
Leadership Shift at Traws Pharma: Chairman Steps Up as CEO Exits, Key Antiviral Programs Continue - Stock Titan
Traws Pharma Reports Promising Preclinical Results for Bird Flu Treatment - MSN
Traws Pharma Announces Promising Data for Ratutrelvir as a COVID-19 Treatment - MSN
Traws Pharma to Host Investor Event on Bird Flu and COVID - GlobeNewswire
Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET - Yahoo Finance
Former CDC Director Unveils Game-Changing Bird Flu and COVID Treatments at Traws Pharma Event - Stock Titan
Traws Pharma presents data on COVID-19 candidate ratutrelvir at ICAR - TipRanks
Traws Pharma’s ratutrelvir shows promise in COVID-19 treatment By Investing.com - Investing.com South Africa
Traws Pharma’s ratutrelvir shows promise in COVID-19 treatment - Investing.com
Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR - GlobeNewswire
Breakthrough: Next-Gen COVID Drug Defeats 18 Variants Without Ritonavir Boost - Stock Titan
Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates - GlobeNewswire
Breakthrough: New Bird Flu Drug Achieves Remarkable 99.9% Viral Reduction in Latest Primate Tests - Stock Titan
Traws Pharma Unveils Promising Bird Flu Treatment Data - MyChesCo
Traws Pharma touts bird flu drug efficacy at ICAR By Investing.com - Investing.com South Africa
Traws Pharma touts bird flu drug efficacy at ICAR - Investing.com
Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR - The Manila Times
Traws Pharma Presents Positive Data For TXM As Bird Flu Treatment At ICAR -March 21, 2025 at 07:03 am EDT - Marketscreener.com
Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR - GlobeNewswire
Breakthrough: Revolutionary Bird Flu Drug Achieves Perfect Survival Rate in Latest Trial Data - StockTitan
Traws Pharma Enters $50 Million ATM Agreement With Citizens JMP Securities -March 10, 2025 at 05:35 pm EDT - Marketscreener.com
Traws Pharma Announces Promising Preclinical Results for Bird Flu Treatment - MSN
PA-based biopharma company reports positive results testing efficacy of bird flu antiviral - Pennsylvania Business Report
TRAW stock touches 52-week low at $2.14 amid sharp annual decline - Investing.com
Traws Pharma, Inc. (NASDAQ:TRAW) Short Interest Update - Defense World
Traws Pharma reports promising bird flu treatment results By Investing.com - Investing.com Canada
Traws Pharma reports promising bird flu treatment results - Investing.com India
Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil - GlobeNewswire
Can Traws Pharma's Single-Dose Treatment Combat the Growing Bird Flu Threat? - StockTitan
Traws Pharma Reports Positive Results From Accepted Bird Flu Model For Anti-Viral Candidate, Tivoxavir Marboxil - Marketscreener.com
Traws Pharma Inc Stock (TRAW) Financials Data
There is no financial data for Traws Pharma Inc (TRAW). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):